Mann Jamie F S, Acevedo Reinaldo, Campo Judith Del, Pérez Oliver, Ferro Valerie A
University of London, St George's, London SW170RE, UK.
Expert Rev Vaccines. 2009 Jan;8(1):103-12. doi: 10.1586/14760584.8.1.103.
Antigens administered via the oral and, to a lesser extent, the nasal route are potentially able to invoke tolerance, resulting in a nonreactive immune response. This has been a hurdle for mucosal vaccine development and yet the desire to induce protective local and systemic responses, with pain-free and more convenient products, has been the impetus driving mucosal vaccine R&D. Nevertheless, few mucosal vaccines have reached the marketplace and products are still treated with caution, particularly where live organisms are utilized. In this review, we examine the use of delivery systems with adjuvant properties as key components in a vaccine strategy that does not require the use of live vectors to overcome tolerance and have exemplified their success in mucosal vaccines, concentrating on the nasal and oral routes of administration.
经口服以及在较小程度上经鼻途径给予的抗原有可能引发耐受性，从而导致无反应性免疫应答。这一直是黏膜疫苗开发的一个障碍，然而，研发无痛且更便捷的产品以诱导保护性局部和全身反应的愿望，一直是推动黏膜疫苗研发的动力。尽管如此，很少有黏膜疫苗进入市场，并且产品仍受到谨慎对待，尤其是在使用活生物体的情况下。在本综述中，我们研究了具有佐剂特性的递送系统作为疫苗策略关键组成部分的应用，该策略无需使用活载体来克服耐受性，并举例说明了它们在黏膜疫苗中的成功，重点关注鼻内和口服给药途径。
